Azeria Takes Aim At Pioneer Factors, New Targets In Oncology

Emerging Company Profile: A pioneer factor is required to be present before estrogen receptors bind to DNA, and is being evaluated as a new anti-tumor target for agents to treat breast and other cancers by Azeria Therapeutics, which recently raised £4m ($5.3m) in a Series A financing.